Prothena Corporation plc

NASDAQ PRTA

Data sourced from

and

Daily

Download Data

Prothena Corporation plc Price to Earnings Ratio (P/E) on June 03, 2024: -36.47

Prothena Corporation plc Price to Earnings Ratio (P/E) is -36.47 on June 03, 2024, a -27.90% change year over year. The price to earnings ratio (P/E ratio) compares the market price per share of a company's stock to its earnings per share (EPS). It is calculated by dividing the market capitalization by the net income, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's earnings. A higher P/E ratio indicates that investors are willing to pay a higher price for each unit of earnings, suggesting higher market expectations for future earnings growth.

Prothena Corporation plc 52-week high Price to Earnings Ratio (P/E) is -13.74 on April 30, 2024, which is 62.34% above the current Price to Earnings Ratio (P/E).
Prothena Corporation plc 52-week low Price to Earnings Ratio (P/E) is -39.02 on May 06, 2024, which is -6.98% below the current Price to Earnings Ratio (P/E).
Prothena Corporation plc average Price to Earnings Ratio (P/E) for the last 52 weeks is -22.82.

NASDAQ: PRTA

Prothena Corporation plc

CEO	Dr. Gene G. Kinney Ph.D.
IPO Date	Dec. 21, 2012
Location	Ireland
Headquarters	77 Sir John Rogerson?s Quay, Dublin, Ireland, 2
Employees	173
Sector	Healthcare
Industry	Biotechnology

Description

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Key trends